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Abstract
Background: We previously identified and characterized a novel 55 kDa nuclear protein, termed
nmt55/p54nrb, whose expression was decreased in a subset of human breast tumors. The objective
of this study was to determine if this reduced expression in human breast tumors was attributed
to the regulation of mRNA transcription or the presence of altered forms of this protein.
Results: Northern blot analysis and ribonuclease protection assay indicated that nmt55/p54nrb
mRNA is expressed at varying levels in estrogen receptor positive (ER+) and estrogen receptor
negative (ER-) human breast tumors suggesting that reduced expression of nmt55/p54nrb protein
in ER- tumors was not due to transcriptional regulation. To determine if multiple protein isoforms
are expressed in breast cancer, we utilized Western blot and immunohistochemical analyses, which
revealed the expression of an nmt55/p54nrb protein isoform in a subset of ER+ tumors. This subset
of ER+ human breast tumors expressed an altered form of nmt55/p54nrb that was undetectable
with an amino-terminal specific antibody suggesting that this isoform contains alterations or
modifications within the amino terminal domain.
Conclusions: Our study indicates that nmt55/p54nrb protein is post-transcriptionally regulated in
human breast tumors leading to reduced expression in ER- tumors and the expression of an amino
terminal altered isoform in a subset of ER+ tumors. The potential involvement of nmt55/p54nrb in
RNA binding and pre-mRNA splicing may be important for normal cell growth and function; thus,
loss or alteration of protein structure may contribute to tumor growth and progression.
Background
Human breast tumorigenesis is a multistage process en-
compassing complex cellular transformation from nor-
malcy to malignancy [1]. It has been proposed that
multiple, different cellular events dictate the biochemi-
cal changes that allow normal cells to become highly ma-
lignant. These key events require alterations in the
expression of many genes, translation of RNA tran-
scripts, and cellular activation by growth factors, hor-
mones and proteins in the evolving tumor cell
population [1–5].
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Steroid hormones play a vital role in the growth of nor-
mal mammary gland tissue, as well as, the development
and progression of breast tumors. Human estrogen re-
ceptor alpha (hERα ) is detected in 50–85% of all breast
tumors [6], and is utilized as a prognostic marker to
identify patients who may have a favorable response to
hormonal or endocrine manipulations. Thus, hERα  pro-
vides a useful prognostic index in patients with metastat-
ic disease and is associated with disease-free survival [7–
10]. However, 35% of all patients with hERα  positive
(ER+) tumors do not respond to hormonal interventions
suggesting cellular and molecular alterations [6,11,12].
This lack of response may be attributed, at least in part,
to the presence of nonfunctional hERα  as determined by
the inability of hERα  to bind hormone, to recognize and
bind to specific DNA-responsive elements and/or its in-
ability to recruit other transcriptional activation factors
[6,11,12]. It may also be attributed to tumor heterogene-
ity in which some tumor cells may continue to express
functional hERα  while other cells may express either
dysfunctional hERα  or do not express hERα  at all. This
may permit the tumor to become autonomous with re-
spect to hormone sensitivity, allowing tumor progres-
sion. Currently, human breast tumor hERα  content is
determined by ligand-binding assays or immunohisto-
chemistry. While these techniques measure either hERα
content or its cellular distribution, they do not provide
the means for assessing hERα  functionality.
In our search for new tumor markers, we identified and
characterized a novel 55 kDa nuclear protein, termed
nmt55 [13]. The amino acid sequence of nmt55 was high-
ly homologous, but not identical, to that reported for the
nuclear protein p54nrb identified in HeLa cells [14]. A
more recent report by Peters et al. [15] noted differences
in the sequence of the reported HeLa cell p54nrb [14] and
placental p54nrb. When we compared the sequences of
nmt55 and placental p54nrb (U. Muller, Personal Com-
munication), we determined that the sequences were
identical. The differences in the sequence for nmt55, pla-
cental p54nrb and HeLa p54nrb are most likely due to
HeLa p54nrb sequencing error. Chromosomal location
and sequence identity data confirm that p54nrb has the
same sequence as nmt55 and are the same gene. We refer
to this protein as nmt55/p54nrb.
Our studies on nmt55 and those of p54nrb have charac-
terized this protein as an RNA binding protein with the
ability to associate with Topoisomerase I and the polypy-
rimidine tract-binding protein associated splicing factor
(PSF) [16–20]. Further, we observed the association of
nmt55/p54nrb with several splicing factors known to be
essential for spliceosome formation suggesting a role for
nmt55/p54nrb in pre-mRNA splicing (unpublished re-
sults).
Our previous studies investigated the protein expression
of nmt55/p54nrb in human breast tumors using a mono-
clonal antibody with an epitope localized to the carboxyl
terminal domain of this protein. These studies demon-
strated a statistically significant association between
nmt55/p54nrb protein expression, tumor hormonal phe-
notype and mean tumor size [13]. Specifically, in tumors
large in size or those tumors which were determined to
be ER-, the expression of nmt55/p54nrb protein was ab-
sent, or greatly reduced [13]. These results suggested
that loss of nmt55/p54nrb protein expression may be re-
lated to hormone insensitivity, tumor differentiation
state, unregulated tumor growth and metastases.
The absence or reduced expression of nmt55/p54nrb may
be attributed to the regulation of mRNA expression, pro-
tein processing of a specific functional domain or the
presence of a heterogeneous population of nmt55/p54nrb
isoforms which may not be immunodetected by mono-
clonal antibody NMT-1. In this study, we compared
mRNA levels in ER+ and ER- human breast tumors us-
ing Northern blot analysis and ribonuclease protection
assay to assess if nmt55/p54nrb is regulated at the tran-
scription level. We further developed, nmt55/p54nrb
specific, site-directed polyclonal antibodies to the amino
terminal region and to a mid-region to assess the poten-
tial presence of multiple nmt55/p54nrb isoforms or proc-
essed nmt55/p54nrb in human breast tumors.
Methods
Isotopes, reagents and chemicals
[2,4,6,7-3H] Oestradiol ([3H] E2) (102 Ci/mmol) was ob-
tained from Amersham (Arlington Heights, IL). α -32P
CTP (800 Ci/mmol) and γ -32P ATP (3000 Ci/mmol)
were obtained from New England Nuclear (Boston, Ma).
Unlabeled diethylstilbestrol (DES) was obtained from
Steraloids (Wilton, NH). Monoclonal antibodies NMT-1
and EVG F9 were developed to unique peptides encom-
passing amino acids 140–154 and 140–154–247–263 of
hERα , respectively [21–24]. Monoclonal antibody 4.14
was raised against a peptide representing amino acid se-
quence 533–547 of human progesterone receptor (hPR)
[25]. All other chemicals were reagent grade and were
obtained from commercial sources.
Human tissue and cell lines
Human breast cancer tissue was obtained from patients
undergoing surgery for the treatment of breast cancer, as
described previously [26]. The MCF-7 human adenocar-
cinoma cell line was obtained from the American Type
Tissue Culture Collection (Manassas, VA).BMC Cancer 2001, 1:15 http://www.biomedcentral.com/1471-2407/1/15
Buffers and solutions
TEGT Buffer consisted of 50 mM Tris-HCl, 10% [vol/vol]
glycerol, 1 mM EDTA, 0.02% [wt/vol] sodium azide and
10 mM monothioglycerol, pH 7.4, at 4°C. TGET/MO
buffer was TGET buffer containing 10 mM sodium mo-
lybdate. TBST buffer consisted of 50 mM Tris-HCl, 0.15
M NaCl, and 0.5% Tween 20, pH 8.0.
Cytosol and nuclear extract preparation
Cytosols were prepared as described [22,27–29]. Briefly,
tissue was homogenized (0.5 g/3 ml) in TEGT/MO buff-
er. The homogenate was centrifuged at 100,000 ×  g for
30 minutes at 4°C and the supernatant fraction (cytosol)
was collected. After the removal of the cytosolic fraction,
the nuclear pellet was resuspended in 1.5 ml of TEGT
buffer containing 0.4 M KCl and incubated on ice for 1
hour with intermittent vortexing. The solubilized pro-
teins were separated from the insoluble chromatin by
centrifugation at 100,000 ×  g for 30 minutes at 4°C. The
supernatant fraction (nuclear extract) was collected and
used immediately for experimentation or frozen at -
80°C.
Estrogen receptor assay
The concentration of unoccupied hERα  was determined
by ligand binding analyses as described previously
[22,27–30]. Briefly, cytosols were incubated with 5 nM
[3H] E2 in the absence (total binding) or presence (non-
specific binding) of a 1000-fold molar excess of unla-
beled DES for 16–20 hours at 4°C. Free radioactivity was
then separated from bound radioactivity by dextran-
coated charcoal (DCC) pellets. In all experiments, non-
specific binding was determined and subtracted from to-
tal binding to obtain specific binding. The binding data
were normalized in femtomoles per milligram (fmol/mg)
of cytosol proteins. We chose a positive cutoff value of 10
fmol/mg protein for hERα  [6,11–13,31,32].
Synthesis and purification of peptides
We have previously used sequence specific peptides to
generate site-directed monoclonal and polyclonal anti-
bodies [21,22,24,25,27,28]. Two peptides, NMT-4 and
NMT-5, were synthesized, purified by gel filtration and
analyzed by HPLC. Analyses of the amino acid composi-
tion correlated well with the primary sequence. The se-
quences of these peptides is given in Figure 1A.
Peptide conjugation and immunization
Keyhole limpet hemocyanin (KLH) and bovine serum al-
bumin (BSA) were dissolved in phosphate-buffered sa-
line (PBS) to give a final concentration of 1 mg/ml. Five
milligrams of each peptide was then dissolved in 5 ml of
the KLH solution or BSA solution. The pH of the mix-
tures was adjusted to 9.0 with 0.1 M LiOH. Coupling of
the peptide to the carrier protein was initiated by drop
wise addition of 6.25% glutaraldehyde to achieve a final
concentration of 1%. Each mixture was incubated at 4°C
for one hour with gentle agitation. Each mixture was
then dialyzed extensively against four changes of PBS.
Aliquots were taken after dialysis to determine efficiency
of coupling and the remaining dialyzed material was
stored at -80°C.
New Zealand White female rabbits were obtained from
Pine Acre Rabbitry (Norton, MA). Prior to immuniza-
tion, serum was collected from each rabbit by bleeding
through the ear artery and this was designated as pre-im-
mune serum. Each animal was immunized by subcutane-
ous injection at multiple sites along the back with a total
of 1 ml of an emulsion made by mixing equal volumes of
complete Freund's adjuvant and KLH-conjugated pep-
tide. The final emulsion contained 500 µg/ml of the de-
sired peptide. After 3 weeks, the animals were boosted
with the antigen in incomplete Freund's adjuvant. Two
weeks after the booster shots the animals were bled, the
sera were collected and tested for the presence of anti-
peptide antibodies by enzyme-linked immunosorbent
assay (ELISA).
RNA preparation and northern blot analyses
Total RNA from MCF-7 cells and human breast tumors
was prepared as described [33]. Total RNA was electro-
phoresed on 1% formaldehyde/MOPS agarose gels and
transferred onto nylon-reinforced nitrocellulose mem-
branes. Northern blot analysis was carried out using
double-stranded DNA probes labeled to a specific activi-
ty of 108 – 109 cpm/µg with α -[32P] CTP using T7 DNA
polymerase and random primers. Hybridization was car-
ried out at 67°C for 2 hours in Quickhyb solution (Strat-
agene, La Jolla, CA). Membranes were exposed to
Hyperfilm (Amersham, Arlington Heights, IL) for 24
Figure 1
Amino acid sequence and molecular localization of the syn-
thetic oligopeptides used to generate human nmt55/p54nrb
polyclonal antibodies.BMC Cancer 2001, 1:15 http://www.biomedcentral.com/1471-2407/1/15
hours at -70°C following low (2X SSC, 0.1% SDS, 25°C)
and high (0.2X SSC, 0.1% SDS, 65°C) stringency washes.
The probe used for nmt55/p54nrb analysis was a 499 bp
SacI/BglII fragment representing the unique carboxyl
terminus of nmt55/p54nrb [13]. This probe was utilized
to prevent cross-hybridization with other homologous
RNA binding proteins. A 545 bp HindIII/Xbal fragment
of human glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) was utilized as a probe to normalize for RNA
loading [34].
Ribonuclease protection assays
Ribonuclease protection assays were performed using
the RPA III Ribonuclease Protection Assay Kit from Am-
bion (Austin, TX) according to the manufacturer's speci-
fications. RNA was isolated and prepared as described
above. A 499 bp nmt55/p54nrb fragment was transcribed
with T7 RNA polymerase in the presence of α -[32P] CTP
and non-radioactive nucleotides to generate an antisense
probe (specific activity of 108 – 109 cpm/µg) or SP6 RNA
polymerase in the presence of non-labeled nucleotides to
generate a sense probe (control). Sample RNA and the
antisense probe were mixed and co-precipitated with 0.5
M ammonium acetate. Samples were hybridized for 18
hours in acetate/citrate buffer, pH 6.8, at 45°C. The hy-
bridization product was digested with an RNase A/T1
mixture. Following digestion, RNase was inactivated and
hybridized RNA was precipitated according to the man-
ufacturer's instructions. Precipitated samples were re-
suspended and analyzed by gel electrophoresis on 5%
urea-polyacrylamide denaturing gels. Following electro-
phoresis, gels were dried for 2 hours at 80°C and subject-
ed to autoradiography for 24 hours at -70°C. Century
markers were radiolabeled according to the manufactur-
er's instructions and used as molecular weight markers.
Electrophoresis and western blot analyses
Polyacrylamide gel electrophoresis and Western blot
analyses were performed as described [13,23]. Briefly,
samples were electrophoresed on 10% resolving sodium
dodecyl sulphate-polyacrylamide gels (SDS/PAGE) ac-
cording to the method of Laemmli [35]. Proteins were
then electrotransferred onto nitrocellulose membranes
and the membranes were incubated in TBST buffer con-
taining 5% nonfat dry milk for 1 hour to block nonspecific
protein binding. Membranes were incubated with pri-
mary antibodies, at various dilutions, for 1 hour and then
washed three times with TBST, 10 minutes each. Nitro-
cellulose membranes were then incubated with the ap-
propriate corresponding horseradish peroxidase-
conjugated secondary antibody for 1 hour and washed as
above. Antibody-protein interactions were detected us-
ing enhanced chemiluminescence (ECL) (Pierce, Rock-
ford, IL) and autoradiography.
Immunohistochemistry
Formalin-fixed, paraffin-embedded blocks of human
breast tissue were re-cut at a thickness of 4 µm, and con-
secutive sections were stained with Gill's hematoxylin
and eosin (H&E) [23]. Immunohistochemical assays
were performed using a modification of the antigen-re-
trieval technique based on microwave exposure. Unless
stated otherwise, all incubations were at 37°C in a hu-
midity chamber, followed by two PBS plus Triton X-100
(1:500) washes, 2 minutes each. Endogenous peroxidase
activity was quenched using a 3% hydrogen peroxide/
methanol solution for 30 minutes at 25°C. This was fol-
lowed by antigen retrieval and subsequent incubation in
blocking reagent (1:50 normal horse serum) for 20 min-
utes. Anti-hERα  monoclonal antibody EVG F9 and anti-
hPR monoclonal antibody 4.14 were diluted 1:200 and
incubated for 30 minutes at 37°C. Anti-nmt55/p54nrb
polyclonal antibodies, NMT-4 and NMT-5, were diluted
1:2500 and incubated for 2 hours at 37°C. Non-immune
mouse IgG was used as a negative control antibody. Sec-
tions were rinsed and incubated with secondary antibody
(rabbit anti-mouse IgG, biotinylated or swine anti-rabbit
IgG, biotinylated) for 30 minutes followed by a 30
minute incubation in Streptavidin solution, using DA-
KO's Quick Staining LSAB Kit (DAKO Corp, Carpinteria,
CA). To visualize antibody binding, tissue sections were
incubated for 10 minutes in 3, 3'-diaminobenzidine
(DAB) at 25°C. Sections were then rinsed in distilled wa-
ter and counterstained for 1 minute in Gill's hematoxylin.
Slides were analyzed by standard light microscopy.
Results
Analysis of nmt55/p54nrb mRNA in ER+ and ER- human 
breast tumors
We have previously shown that nmt55/p54nrb protein
was expressed in most ER+/PR+ human breast tumors
but was undetectable in ER-/PR- human breast tumors
[13]. Since loss of hERα  expression is associated with
poor prognosis and continued expression of hERα  is as-
sociated with disease-free survival and correlates well
with tumor differentiation state, we wanted to investi-
gate the regulation of nmt55/p54nrb expression. To test
the possibility that nmt55/p54nrb may be transcription-
ally downregulated in ER- tumors, we analyzed mRNA
levels from a series of human breast tumors utilizing
Northern blot analyses and ribonuclease protection as-
says.
Figure 2 shows Northern blot analysis of nmt55/p54nrb
mRNA expression in 12 human breast tumors. MCF-7
cells (Lane M), used as a control, express an abundant
2.6 kb mRNA transcript for nmt55/p54nrb. nmt55/
p54nrb transcripts were detected at varying levels in both
ER+ and ER- tumors. mRNA transcript was expressed at
high levels (lanes 2, 3, 5, 9, 11 and 12) moderate levelsBMC Cancer 2001, 1:15 http://www.biomedcentral.com/1471-2407/1/15
(lanes 2, 7 and 10) or low levels (lanes 1, 4 and 8). The tu-
mor sample in lane 6 was degraded and was not analyzed
further. These different nmt55/p54nrb mRNA levels
were not due to differential RNA loading, as GAPDH lev-
els were similar in all tumor samples. These results sug-
gest that nmt55/p54nrb mRNA transcripts are expressed
at various levels. It also suggested that nmt55/p54nrb
protein expression in some breast tumors does not cor-
relate with nmt55/p54nrb mRNA expression. Specifical-
ly, the decreased nmt55/p54nrb protein expression
observed in ER- human breast tumors may not be attrib-
uted to transcriptional regulation of nmt55/p54nrb
mRNA since mRNA expression in ER- tumors is not uni-
versally decreased.
To confirm these observations, ribonuclease protection
assay was utilized to analyze a set of different human
breast tumors. As shown in Figure 3, all human tumor
samples expressed nmt55/p54nrb mRNA transcript.
nmt55/p54nrb mRNA was not detected in calf uterine tis-
sue. This was expected since the nmt55/p54nrb probe
utilized for detection is of human origin and calf uterus
tissue expresses a different transcript for nmt55/p54nrb.
This prevents high fidelity hybridization between the
probe and the mRNA allowing complete mRNA probe di-
gestion. Based on the data presented in Figures 2 and 3,
it appears that nmt55/p54nrb mRNA is expressed inde-
pendent of tumor hormonal status suggesting that
nmt55/p54nrb mRNA is not regulated by hERα . These
results, together with those reported previously [13], fur-
ther suggest that decreased expression of nmt55/p54nrb
protein in ER- human breast tumors is likely a post-tran-
scriptional event.
Immunochemical detection of multiple nmt55/p54nrb pro-
tein isoforms in human breast tumors
Since there was no apparent nmt55/p54nrb mRNA regu-
lation in ER+ or ER- human breast tumors, it was possi-
ble that monoclonal antibody NMT-1 may not detect the
presence of potential multiple isoforms of nmt55/p54nrb
protein especially in ER- tumors. This necessitated the
development of domain specific antibodies. To this end,
two peptides were synthesized and purified based on se-
lected sequences in the subdomains of human nmt55/
p54nrb (Figure 1A). These selected peptides were re-
ferred to as NMT-4 and NMT-5 and represent sequences
56–72 and 371–386 of human nmt55/p54nrb, respective-
ly (Figure 1A). Polyclonal antibodies were developed
against these peptides; polyclonal antibody NMT-4 rec-
ognized a sequence in the amino terminal region of
nmt55/p54nrb and polyclonal antibody NMT-5 recog-
nized a sequence in a mid-region of nmt55/p54nrb (Fig-
ure 1B).
Figure 4 shows the binding of polyclonal antibodies
NMT-4 and NMT-5 to a protein with an estimated mo-
lecular weight of 55 kDa (lanes 3 and 5 respectively). Pre-
immune sera detected no specific protein in the 55 kDa
range (lanes 1 and 2). Specificity of the polyclonal anti-
Figure 2
Northern blot analysis of nmt55/p54nrb mRNA expression in
MCF-7 cells and ER+/ER- Human Breast tumors. Total RNA
(20 µg) was prepared from MCF-7 cells (lane M) and twelve
different human breast tumors (lanes 1–12). The RNA was
subjected to hybridization with a human nmt55/p54nrb 499
bp SacI/BglII radiolabeled probe (top panel) or a human glyc-
eraldehyde-3-phosphate (GAPDH) 545 bp HindIII/Xbal radi-
olabeled probe to indicate levels of RNA loading (bottom
panel). Estrogen receptor (ER) expression levels were deter-
mined by ligand binding assay and are indicated along the top
of the figure.
Figure 3
Ribonuclease protection assay of nmt55/p54nrb mRNA
expression in MCF-7 cells and ER+/ER- Human Breast
tumors. Total RNA (20 µg) was prepared from MCF-7 cells
(lane M), ten different human breast tumors (lanes 1–10) and
calf uterus tissue (lane C). The RNA was subjected to hybrid-
ization with a human nmt55/p54nrb 499 bp SacI/BglII radiola-
beled probe. The total RNA/radiolabeled probe mixtures
were then digested and separated as described in Materials
and Methods. Lane P indicates radiolabeled probe alone,
which was not subjected to RNase digestion. Lane R repre-
sents radiolabeled probe alone that was digested with the
RNase mixture. Estrogen receptor (ER) expression levels
were determined by ligand binding assay and are indicated
along the top of the figure. Estimated molecular weight is
indicated in the MW lane.BMC Cancer 2001, 1:15 http://www.biomedcentral.com/1471-2407/1/15
bodies was assessed by pre-incubation with the appro-
priate immunogenic free peptides. As shown in Figure 4
(lanes 4 and 6), the antigenic peptides competed effec-
tively for the binding of the antibodies to the protein in-
dicating that these antibodies are specific. Complete
displacement was not seen in Lane 6 which was due to
high titer of the antibody. Incubation of NMT-5 antibody
with a higher concentration of free immunogenic NMT-
5 peptide resulted in complete displacement (results not
shown). These results indicate that the anti-peptide pol-
yclonal antibodies, NMT-4 and NMT-5, detect this 55
kDa protein with high specificity and high affinity.
Since nmt55/p54nrb belongs to a family of RNA binding
proteins with conserved domains, it was possible that the
polyclonal antibodies NMT-4 and NMT-5 were detecting
a protein with a similar molecular weight. To investigate
this possibility, we carried out immunoprecipitation as-
says of MCF-7 nuclear extract with a series of antibodies,
and immunoblotted with the same series of antibodies.
Figure 5 shows MCF-7 nuclear extract immunoprecipi-
tated with monoclonal antibody NMT-1, polyclonal anti-
body NMT-4, polyclonal antibody NMT-5 or monoclonal
antibody EVG F9. The immunoprecipitate samples were
then separated by SDS/PAGE and immunoblotted with
monoclonal antibody NMT-1 (top panel), polyclonal an-
tibody NMT-4 (middle panel) or polyclonal antibody
NMT-5 (bottom panel). The results show that this 55 kDa
protein is detected regardless of which antibody is used
for immunoprecipitation or immunoblotting. Since
monoclonal antibody NMT-1 is specific for nmt55/
p54nrb protein [13], the results suggest that polyclonal
antibodies NMT-4 and NMT-5 are specific to nmt55/
p54nrb and do not detect related RNA binding proteins.
nmt55/p54nrb protein was not detected in the anti-hERα
monoclonal antibody EVG F9 immunoprecipitation
sample (negative control). Monoclonal antibody NMT-1
and polyclonal antibodies NMT-4 and NMT-5 also detect
bacterially expressed partially purified nmt55/p54nrb
protein (results not shown). These results indicate that
monoclonal antibody NMT-1 (carboxyl terminal) and the
polyclonal antibodies NMT-4 (amino terminal) and
NMT-5 (mid-region) detect nmt55/p54nrb protein with
high affinity and high specificity.
Figure 6 shows Western blot analysis of nuclear extracts
from 10 human breast tumor immunoblotted with poly-
clonal antibodies NMT-4 (top panel), NMT-5 (middle
panel) and monoclonal antibody NMT-1 (bottom panel).
No antibodies detected nmt55/p54nrb protein in ER- hu-
Figure 4
Assessment of NMT-4 and NMT-5 polyclonal antibody spe-
cificity for nmt55/p54nrb. MCF-7 nuclear extract (50 µg) was
separated by SDS/PAGE and subjected to Western blot anal-
ysis. Lanes 1 and 2 represent immunodetection with NMT-4
pre-immune serum and NMT-5 pre-immune serum, respec-
tively. Lanes 3 and 5 represent immunodetection with poly-
clonal antibodies NMT-4 and NMT-5, respectively. Lane 4
represents MCF-7 nuclear extract immunoblotted with poly-
clonal antibody NMT-4 pre-incubated with its corresponding
immunogenic peptide. Lane 6 represents MCF-7 nuclear
extract immunoblotted with polyclonal antibody NMT-5 pre-
incubated with its corresponding immunogenic peptide. Right
hand margin represents estimated molecular weight.
Figure 5
Imimunoprecipitation and immunodetection of nmt55/p54nrb
protein with specific site-directed antibodies raised against
various domains of nmt55/p54nrb. MCF-7 cell nuclear
extracts (50 µg) were subjected to immunoprecipitation
assays with the antibodies indicated along the top margin.
Lane 1 represents immunoprecipitation with monoclonal
antibody EVG F9 (raised against human estrogen receptor
alpha), lane 2 monoclonal antibody NMT-1, lane 3 polyclonal
antibody NMT-4 and lane 4 polyclonal antibody NMT-5.
Immunoprecipitated samples were separated by SDS/PAGE
and analyzed by Western blot. Left margin indicates the anti-
bodies used for immunodetection. Top panel represents
immunodetection with monoclonal antibody NMT-1, middle
panel polyclonal antibody NMT-4 and bottom panel polyclo-
nal antibody NMT-5.BMC Cancer 2001, 1:15 http://www.biomedcentral.com/1471-2407/1/15
man breast tumors (lanes 1–5) confirming previous ob-
servations [13]. Monoclonal antibody NMT-1 and
polyclonal antibody NMT-5 detect nmt55/p54nrb protein
in all ER+ tumor samples (lanes 5–10), albeit at varying
levels. Interestingly however, polyclonal antibody NMT-
4 detected nmt55/p54nrb in only 3 out of 5 ER+ tumors.
These results have been reproduced in the nuclear ex-
tracts of approximately forty human breast tumors sug-
gesting that there is an alteration or modification in the
amino terminal domain of nmt55/p54nrb that prevents
polyclonal antibody NMT-4 from binding to nmt55/
p54nrbprotein. The observations made here further sug-
gest the presence of nmt55/p54nrb variants in a subset of
ER+ human breast tumors.
Detection of nmt55/p54nrb by Western blot analyses re-
quires tumor pulverization, homogenization, fractiona-
tion and the preparation of cellular extracts. These
manipulations may result in biochemical alterations of
nmt55/p54nrb during processing. To insure that this ob-
servation was not the result of experimental manipula-
tion, and indeed the nmt55/p54nrb variants detected
with polyclonal antibody NMT-5 and monoclonal anti-
body NMT-1 but not polyclonal antibody NMT-4 were
also expressed in intact cells, we utilized immunohisto-
chemical analyses in human breast tumor tissue sec-
tions. Further, immunohistochemistry permits the
assessment of nmt55/p54nrb subcellular localization and
distribution within human breast tumors.
Figure 7 shows immunohistochemical analyses of a hu-
man breast tumor using hERα , hPR and nmt55/p54nrb
specific antibodies. Tissue sections stained positively
with monoclonal antibodies EVG F9 (Panel A) and 4.14
(Panel B) showing the expression of hERα  and hPR, re-
spectively. Positive staining with polyclonal antibodies
NMT-4 (Panel C) and NMT-5 (Panel D) showed the pres-
ence of nmt55/p54nrb. Figure 8 represents a tumor
which exhibited positive staining for hERα  (Panel A),
hPR (Panel B), and nmt55/p54nrb when utilizing poly-
clonal antibody NMT-5 (Panel D). However, this tumor
did not stain positive for nmt55/p54nrb when polyclonal
antibody NMT-4 was utilized (Panel C). Similar results
have been observed in sixteen different human breast tu-
mor tissue sections. The immunohistochemistry data
confirm the results obtained by Western blot analyses,
suggesting that nmt55/p54nrb protein is expressed in
various isoforms in a subset of ER+ human breast tu-
mors. The nature of the alteration or modification in the
amino-terminal region of nmt55/p54nrb, which prevents
the detection of nmt55/p54nrb by polyclonal antibody
NMT-4 by Western blot and immunohistochemical anal-
yses, remains to be determined.
Discussion
We have previously investigated nmt55/p54nrb protein
expression in human breast tumors and observed a sta-
tistically significant association between decreased
nmt55/p54nrb expression, loss of hERα  and hPR and in-
creased tumor size [13]. It is possible that decreased
nmt55/p54nrb expression represents poor tumor differ-
entiation, increased tumor growth and metastases since
reduced or absent hERα  expression and function corre-
lates with poor tumor differentiation [11,36] and tumor
size is a strong indicator of tumor progression [37]. Here
we investigated nmt55/p54nrb mRNA expression using
Northern blot analyses and ribonuclease protection as-
says to determine if the reduction of nmt55/p54nrb pro-
tein expression was the result of transcriptional
regulation. mRNA transcripts for nmt55/p54nrb showed
similar expression in human breast tumors and were not
related to hERα  expression. These results suggest that
the regulation of nmt55/p54nrb protein expression ob-
served in human breast tumors is likely a post-transcrip-
tional event.
Results from Western blot analyses with polyclonal anti-
bodies NMT-4 and NMT-5 showed that nmt55/p54nrb
expression was absent, or greatly reduced, in most of ER-
tumors. This confirmed the previous observations ob-
tained with monoclonal antibody NMT-1 [13]. Data also
showed that a subset of ER+ tumors expressed nmt55/
p54nrb protein detectable with polyclonal antibody
NMT-5 and monoclonal antibody NMT-1 but not poly-
clonal antibody NMT-4. These results suggested the
Figure 6
Detection of nmt55/p54nrb protein isoforms by Western
Blot Analysis using NMT-4, NMT-5 and NMT-1 antibodies.
MCF-7 cell nuclear extract (50 µg), lane M, and ten different
human breast tumor nuclear extracts (50 µg), lanes 1–10,
were separated by SDS/PAGE and subjected to Western blot
analysis with polyclonal antibody NMT-4 (Top Panel), poly-
clonal antibody NMT-5 (Middle Panel) and monoclonal anti-
body NMT-1 (Bottom Panel). Estrogen receptor (ER)
expression levels were determined by ligand binding assay
and are indicated along the top of the figure.BMC Cancer 2001, 1:15 http://www.biomedcentral.com/1471-2407/1/15
presence of nmt55/p54nrb variants in a subset of ER+
human breast tumors. The inability of polyclonal anti-
body NMT-4 to detect nmt55/p54nrb in some ER+ tu-
mors may be attributed to proteolysis during nuclear
extraction and analyses or biochemical modification of
functionally distinct isoform. While the altered molecu-
lar weight of the protein sample shown in Figure 6, lane
9 may be attributed to proteolysis, most of the protein
samples in Figure 6 displayed a similar estimated molec-
ular weight of 55 kDa. Thus, the lack of nmt55/p54nrb
protein detection in this study is most likely not due to
proteolysis. We also wanted to determine if nmt55/
p54nrb variants detected with polyclonal antibody NMT-
5 and monoclonal antibody NMT-1 but not polyclonal
antibody NMT-4 using nuclear extracts and Western blot
analyses were also detectable in intact cells. To test this
premise, we utilized immunohistochemistry to detect
nmt55/p54nrb protein in human breast tumor tissue sec-
tions. The data from immunohistochemistry confirmed
the results obtained by Western blot analyses, which sug-
gested that nmt55/p54nrb protein was expressed in vari-
ous isoforms in a subset of ER+ human breast tumors.
These potential isoforms may have altered biological
function due to the loss of domain specific interactions.
We have attempted to ascertain the presence and nature
of these isoforms by utilizing mixing experiments; how-
ever, these experiments have proved inconclusive. The
expression and role of this isoform in human breast can-
cer remains to be determined.
A plausible explanation for the lack of nmt55/p54nrb
protein detection with polyclonal antibody NMT-4 is a
point mutation in the epitope for polyclonal antibody
NMT-4, a post-translational modification, such as phos-
phorylation, in or near this epitope or an alternative
splice variant affecting this epitope. Another possibility
is the methylation of arginine residues; although this
would not alter the overall charge of the protein, it could
sterically hinder the protein/antibody interaction. The
methylation of arginine residues has been shown to take
Figure 7
Immunohistochemical Analyses of Estrogen Receptor, Pro-
gesterone Receptor and nmt55/p54nrb in a Human Breast
Tumor. Human breast tumor tissue was fixed, embedded,
sectioned and subjected to immunohistochemical analysis
with antibodies to human estrogen receptor alpha (hERα ),
human progesterone receptor (hPR) and nmt55/p54nrb.
Panel A represents immunostaining with monoclonal anti-
body EVG F9 raised against hERα . Panel B represents immu-
nostaining with monoclonal antibody 4.14 raised against hPR.
Panels C and D represent immunostaining with anti-nmt55/
p54nrb polyclonal antibodies NMT-4 and NMT-5, respec-
tively.
Figure 8
Detection of nmt55/p54nrb protein variants by immunohisto-
chemical analyses with NMT-4 and NMT-5 antibodies in a
Human Breast tumor. Human breast tumor tissue was fixed,
embedded, sectioned and subjected to immunohistochemical
analysis with antibodies to human estrogen receptor alpha
(hERα ), human progesterone receptor (hPR) and nmt55/
p54nrb. Panel A represents immunostaining with monoclonal
antibody EVG F9 raised against hERα . Panel B represents
immunostaining with monoclonal antibody 4.14 raised against
hPR. Panels C and D represent immunostaining with anti-
nmt55/p54nrb polyclonal antibodies NMT-4 and NMT-5,
respectively.BMC Cancer 2001, 1:15 http://www.biomedcentral.com/1471-2407/1/15
place in other pre-mRNA splicing proteins though the
role of this modification is unknown [38]. One approach
to determine the presence of a point mutation or a splice
variant is to perform PCR coupled with sequencing tech-
niques. Another approach to resolve this issue is to ana-
lyze this protein isoform by Mass Spectroscopy. These
studies are currently under investigation.
In this report, we show that nmt55/p54nrb protein is ex-
pressed in a variant isoform in a subset of ER+ tumors.
These data, along with our previous observations, sug-
gest that the association of nmt55/p54nrb and hERα  ex-
pression represents three separate human breast tumor
phenotypes. The first phenotype represents tumors that
express wild type nmt55/p54nrb and are ER+. These tu-
mors may be classified as low grade or early stage tumors
and respond well to endocrine manipulations. The sec-
ond phenotype is identified as ER+ using Western blot or
immunohistochemical analyses and would express the
amino terminal altered/modified nmt55/p54nrb iso-
form. This may represent mid-grade and mid-stage tu-
mors which are very heterogeneous. It would be of
interest to determine if these tumors express nonfunc-
tional hERα  and, as a result, do not respond to hormonal
therapy. Finally, the third phenotype represents tumors
that do not express hERα  and nmt55/p54nrb. These tu-
mors would most likely be highly proliferative, classified
as high grade and late stage, hormone insensitive and po-
tentially metastatic. While the focus of this study has
been the biochemical relationship between nmt55/
p54nrb and tumor hormonal status, a more expansive
study correlating nmt55/p54nrb protein expression with
various breast tumor clinicopathological characteristics
may provide additional key information. These studies
are under investigation.
Our data suggests that nmt55/p54nrb may be critical to
cell growth and function, such that, decreased nmt55/
p54nrb expression in ER- human breast tumors or the ex-
pression of nmt55/p54nrb variants in ER+ tumors may
indicate loss of normal growth, nmt55/p54nrb has been
shown in several studies to bind RNA and interact with
PSF and Topoisomerase I [14,16–20,39]. Those results
along with our observations that nmt55/p54nrb associ-
ates with several splicing factors essential for spliceo-
some formation (unpublished) and relates to tumor
hormonal status [13] suggest that nmt55/p54nrb may be
involved in pre-mRNA processing. Thus, loss of nmt55/
p54nrb protein or the expression of nmt55/p54nrb pro-
tein variants in tumor cells may result in the loss of hERα
expression, the expression of nonfunctional hERα  or the
altered expression other critical cell growth factors due
to lack of proper pre-mRNA splicing.
Specifically, the role of nmt55/p54nrb as a splicing factor
may affect hERα  structure and function. The progression
of breast cancer may be associated with changes in RNA
processing and the production of aberrantly spliced mR-
NAs, which may result in non-functional gene products
or the loss of specific gene expression. It has been pro-
posed that loss of hERα  expression in breast tumors is
the result of aberrant RNA processing [40–43]. These
aberrantly spliced mRNAs, if translated, could lead to
truncated receptors with hormone binding but not DNA
binding function [44]. Further, there is evidence for the
role of RNA processing in oncogenesis [45,46]. Many
studies, including those on human hnRNP A2/B1 and
the CD44 gene, suggest that high fidelity pre-mRNA
splicing is critical to normal cellular function and may
play a key role in oncogenesis and breast cancer progres-
sion [47,48]. The strong association between nmt55/
p54nrb and hERα  expression indicates that nmt55/
p54nrb may be an important marker for breast cancer
progression. The decreased or altered expression of
nmt55/p54nrb may be related to tumor differentiation,
unregulated tumor cell growth and metastases and may
explain tumor heterogeneity, especially with respect to
hormonal interventions in the course of treatment. Al-
though an RNA splicing protein, hnRNP A2/B1, has been
used as a tumor marker in lung cancer progression [47],
this is the first time that a protein involved in pre-mRNA
splicing has been implicated in breast cancer progression
and may represent an important breast tumor marker.
Further studies are necessary to determine a functional
link between this RNA binding protein and hERα  in hu-
man breast cancer.
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